Company intelligence / Profile preview
Beimei Pharma
Shenzhen, Guangdong Sheng, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Beimei Pharma has 4 approved pediatric/children’s drugs on the market with a pipeline exceeding 40 products, including several innovative drugs with global or China rights and intellectual property; clinical trial activity (e.g., bilastine oral solution) indicates late-stage development in at least some programs
- Therapeutic areas
- ImmunologyEndocrinologyInfectious DiseasesGastroenterologyDermatologyPulmonologyOtherNeurology
- Modalities
- Small moleculeBiologic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Sol-Gel TechnologiesHeteroCiplaDeva
Beyond the preview
Go deeper on Beimei Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Beimei Pharma.